Information Provided By: 
Fly News Breaks for October 17, 2016
VRX
Oct 17, 2016 | 13:51 EDT
Wells Fargo analyst David Maris said that, traditionally, brands facing the type of generic competition that Valeant's Wellbutrin XL faces see erosion in "the 90% range" and he wonders how the drug still shows growth despite having ten generic competitors. Maris concludes that the answer to that question is "pricing," and goes on to state that his review concludes that the company's pricing strategy for Wellbutrin XL is "unsustainable." The analyst maintains an Underperform rating on Valeant shares.
News For VRX From the Last 2 Days
There are no results for your query VRX
